Summary

A new treatment for severe asthma and COPD, using the monoclonal antibody benralizumab, could revolutionize care after a 50-year stagnation in treatment methods.

A trial showed that a single high-dose injection during flare-ups was 30% more effective than standard steroid tablets, reducing hospital visits and improving quality of life.

The drug targets eosinophils, a cause of inflammation in many attacks.

Researchers highlight its potential safety, fewer side effects compared to steroids, and home-use feasibility, though experts stress the need for increased lung health research funding.